Description: Founded in 2006, Israel-based IceCure Medical develops and markets an advanced liquid-nitrogen-based cryoablation therapy for the treatment of tumors (benign and cancerous) by freezing, with the primary focus areas being breast, kidney, bone and lung cancer. Its minimally-invasive technology is a safe and effective alternative to hospital surgical tumor removal that is easily performed in a relatively short procedure. The system is marketed and sold worldwide, after receiving FDA and CE approvals.
Home Page: www.icecure-medical.com
ICCM Technical Analysis
7 Ha’Eshel Street
Caesarea,
3079504
Israel
Phone:
972 4 623 0333
Officers
| Name | Title |
|---|---|
| Mr. Eyal Shamir | CEO & Director |
| Mr. Ronen Tsimerman CPA | CFO & COO |
| Ms. Tlalit Bussi Tel-Tzure | VP of Bus. Devel. & Global Marketing |
| Ms. Merav Nir Dotan | VP of HR |
| Mr. Naum Muchnik | VP of Research, Devel. & Engineering |
| Mr. Shay Levav | VP of Regulatory and Quality Assurance & Clinical Applications |
Exchange: NASDAQ
Country: US
Currency: US Dollar ($)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 2.4098 |
| Price-to-Sales TTM: | 10.749 |
| IPO Date: | 2021-08-26 |
| Fiscal Year End: | December |
| Full Time Employees: | 55 |